Thomas Bartl (@thomasbartlmd) 's Twitter Profile
Thomas Bartl

@thomasbartlmd

Gynecogic Oncologist・Junior Faculty @MedUni_Wien ・Editorial Fellow @IJGConline

ID: 1875490174060101632

calendar_today04-01-2025 10:31:25

9 Tweet

43 Followers

64 Following

Manel Montesinos-Albert (@mmontesinos_alb) 's Twitter Profile Photo

Thank you so much for the warm welcome! I am very excited to contribute to impactful research, collaborate with such an inspiring group, and learn from the incredible IJGC community. I look forward to growing together and making a difference! #EditorialFellows #IJGC

IJGC (@ijgconline) 's Twitter Profile Photo

Excited to have Thomas Bartl join the inaugural cohort of #IJGC #EditorialFellows for #2025! πŸŽ‰ Beginning his #ESGO Fellowship at the Medical University of #Vienna, Dr. Bartl brings incredible expertise and passion to the team!πŸ‘₯ Pedro T Ramirez Arthur_HC_Hsu Aarthi S Jayraj

Excited to have <a href="/thomasbartlMD/">Thomas Bartl</a> join the inaugural cohort of #IJGC #EditorialFellows for #2025! πŸŽ‰ 
Beginning his #ESGO Fellowship at the Medical University of #Vienna, Dr. Bartl brings incredible expertise and passion to the team!πŸ‘₯ 

<a href="/pedroramirezMD/">Pedro T Ramirez</a> <a href="/HsuMd/">Arthur_HC_Hsu</a> <a href="/JayrajAarthi/">Aarthi S Jayraj</a>
Thomas Bartl (@thomasbartlmd) 's Twitter Profile Photo

🚩Every third physician treating gynecologic cancer patients lacks confidence in managing checkpoint inhibitor side effects, underscoring the need for more specialized training and stronger interdisciplinary collaboration. #gynonc #oncoalert AGO Austria doi.org/10.1186/s12885…

IJGC (@ijgconline) 's Twitter Profile Photo

🌟 #IJGCconversations 🌟 Our EIC, Pedro T Ramirez, had an incredible discussion with the IJGC Fellows about the #2025SpecialIssue topic: Rare Gynecologic Cancers πŸŽ™οΈπŸ’‘ Don’t miss this insightful conversation on the latest research and advancements in the field! πŸ”¬βœ¨ 🎧

Thomas Bartl (@thomasbartlmd) 's Twitter Profile Photo

The low incidence of mucinous ovarian cancer continues to hinder both clinical and translational research. Prognosis remains unchanged for decadesβ€”with no Phase III trials in sight. It's time to shift the paradigm and drive progress!

ESGO (@esgo_society) 's Twitter Profile Photo

πŸ—£οΈ ICYMI: This week we learned The International Journal of Gynecological Cancer’s impact factor rose to 4.7! πŸ“ˆ Congratulations to Pedro Ramirez, the editor-in-chief and his great team of editors! πŸ’ The IJGC is a joint project of ESGO & IGCS πŸ‘‰ …l-journal-of-gynecological-cancer.com

πŸ—£οΈ ICYMI: This week we learned The International Journal of Gynecological Cancer’s impact factor rose to 4.7! πŸ“ˆ Congratulations to Pedro Ramirez, the editor-in-chief and his great team of editors! πŸ’

The IJGC is a joint project of ESGO &amp; IGCS πŸ‘‰ …l-journal-of-gynecological-cancer.com